Hotgen(SH:688068) Xin Lang Cai Jing·2025-10-23 03:12Group 1 - The core viewpoint of the news is that 热景生物 (Hotgen Biotech) has experienced a decline in stock price, dropping 5.11% to 163.36 CNY per share, with a total market capitalization of 15.145 billion CNY [1] - The company has seen a cumulative decline of 5.55% over the past three days, indicating a downward trend in its stock performance [1] - Hotgen Biotech specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments, with its main revenue sources being testing reagents (70.87%), testing instruments (19.79%), and others [1] Group 2 - 华富基金 (Huafu Fund) has a significant holding in Hotgen Biotech, with its fund 华富健康文娱灵活配置混合A (001563) reducing its stake by 18,000 shares in the second quarter, now holding 32,000 shares, which constitutes 6.06% of the fund's net value [2] - The fund has incurred a floating loss of approximately 281,600 CNY today and a total floating loss of 323,800 CNY during the three-day decline [2] - 华富健康文娱灵活配置混合A has shown a year-to-date return of 43.71% and a one-year return of 31.37%, ranking 1265 out of 8159 and 2142 out of 8030 respectively [2]